ArcherDX And BioChain To Provide NGS-characterized FFPE Tumor Samples

BOULDER, Colo.--(BUSINESS WIRE)--ArcherDX, Inc., the leader in NGS-based gene fusion detection, has announced a non-exclusive agreement with BioChain, Inc., the leader in high-quality processed bio-sample products. Under terms of the agreement, BioChain will supply ArcherDX with multiple types of tumor FFPE samples, including NSCLC samples, which will be comprehensively screened for oncogenic fusions, copy number variations (CNVs), single nucleotide variants (SNVs) and insertions/deletions (indels) using the Archer VariantPlex™ and FusionPlex™ Solid Tumor assays. Once characterized, the FFPE tumor samples will be available to the cancer research community through BioChain under their CancerSeq™ Plus brand. “There’s an unmet need for mutation-positive FFPE samples, specifically for genes like RET, NTRK, and MET,” said Jason Myers, CEO and co-founder of ArcherDX. “By working with BioChain to make these known-positive FFPE samples available to our customers, we are resolving a major bottleneck in translational research.”

Help employers find you! Check out all the jobs and post your resume.